Literature DB >> 21840936

Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease.

Georgios Karamanlidis1, Victor Bautista-Hernandez, Francis Fynn-Thompson, Pedro Del Nido, Rong Tian.   

Abstract

BACKGROUND: The outcome of the surgical repair in congenital heart disease correlates with the degree of myocardial damage. In this study, we determined whether mitochondrial DNA depletion is a sensitive marker of right ventricular (RV) damage and whether impaired mitochondrial DNA (mtDNA) replication contributes to the transition from compensated hypertrophy to failure. METHODS AND
RESULTS: RV samples obtained from 31 patients undergoing cardiac surgery were compared with 5 RV samples from nonfailing hearts (control). Patients were divided into compensated hypertrophy and failure groups, based on preoperative echocardiography, catheterization, and/or MRI data. Mitochondrial enzyme activities (citrate synthase and succinate dehydrogenase) were maintained during hypertrophy and decreased by ≈40% (P<0.05 versus control) at the stage of failure. In contrast, mtDNA content was progressively decreased in the hypertrophied RV through failure (by 28±8% and 67±11%, respectively, P<0.05 for both), whereas mtDNA-encoded gene expression was sustained by increased transcriptional activity during compensated hypertrophy but not in failure. Mitochondrial DNA depletion was attributed to reduced mtDNA replication in both hypertrophied and failing RV, and it was independent of PGC-1 downregulation but was accompanied by reduced expression of proteins constituting the mtDNA replication fork. Decreased mtDNA content in compensated hypertrophy was also associated with pathological changes of mitochondria ultrastructure.
CONCLUSIONS: Impaired mtDNA replication causes early and progressive depletion of mtDNA in the RV of the patients with congenital heart disease during the transition from hypertrophy to failure. Decreased mtDNA content probably is a sensitive marker of mitochondrial injury in this patient population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840936      PMCID: PMC3218261          DOI: 10.1161/CIRCHEARTFAILURE.111.961474

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  31 in total

Review 1.  Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy.

Authors:  William Lewis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01       Impact factor: 4.733

Review 2.  Mitochondrial respiratory-chain diseases.

Authors:  Salvatore DiMauro; Eric A Schon
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

3.  Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair.

Authors:  Judith Therrien; Yves Provost; Naeem Merchant; William Williams; Jack Colman; Gary Webb
Journal:  Am J Cardiol       Date:  2005-03-15       Impact factor: 2.778

Review 4.  Pulmonary regurgitation: not a benign lesion.

Authors:  Beatriz Bouzas; Philip J Kilner; Michael A Gatzoulis
Journal:  Eur Heart J       Date:  2005-01-07       Impact factor: 29.983

5.  Chronic stimulation of rat skeletal muscle induces coordinate increases in mitochondrial and nuclear mRNAs of cytochrome-c-oxidase subunits.

Authors:  D A Hood; R Zak; D Pette
Journal:  Eur J Biochem       Date:  1989-02-01

6.  Mitochondrial citric acid cycle and related enzymes: adaptive response to exercise.

Authors:  J O Holloszy; L B Oscai; I J Don; P A Molé
Journal:  Biochem Biophys Res Commun       Date:  1970-09-30       Impact factor: 3.575

7.  Mechanism of mammalian mitochondrial DNA replication: import of mitochondrial transcription factor A into isolated mitochondria stimulates 7S DNA synthesis.

Authors:  S Gensler; K Weber; W E Schmitt; A Pérez-Martos; J A Enriquez; J Montoya; R J Wiesner
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

8.  Release of replication termination controls mitochondrial DNA copy number after depletion with 2',3'-dideoxycytidine.

Authors:  Timothy A Brown; David A Clayton
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

9.  Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot.

Authors:  J G Murphy; B J Gersh; D D Mair; V Fuster; M D McGoon; D M Ilstrup; D C McGoon; J W Kirklin; G K Danielson
Journal:  N Engl J Med       Date:  1993-08-26       Impact factor: 91.245

10.  Magnetic resonance imaging to assess the hemodynamic effects of pulmonary valve replacement in adults late after repair of tetralogy of fallot.

Authors:  Hubert W Vliegen; Alexander van Straten; Albert de Roos; Arno A W Roest; Paul H Schoof; Aeilko H Zwinderman; Jaap Ottenkamp; Ernst E van der Wall; Mark G Hazekamp
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

View more
  44 in total

Review 1.  Mitochondrial Dynamics and Heart Failure.

Authors:  A A Knowlton; T T Liu
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 2.  Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies.

Authors:  Anne A Knowlton; Le Chen; Zulfiqar A Malik
Journal:  J Cardiovasc Pharmacol       Date:  2014-03       Impact factor: 3.105

Review 3.  First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

Authors:  Hazel H Szeto
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 4.  Calcineurin signaling in the heart: The importance of time and place.

Authors:  Valentina Parra; Beverly A Rothermel
Journal:  J Mol Cell Cardiol       Date:  2016-12-20       Impact factor: 5.000

5.  Pressure-overload hypertrophy of the developing heart reveals activation of divergent gene and protein pathways in the left and right ventricular myocardium.

Authors:  Ingeborg Friehs; Douglas B Cowan; Yeong-Hoon Choi; Kendra M Black; Reanne Barnett; Manoj K Bhasin; Christian Daly; Simon J Dillon; Towia A Libermann; Francis X McGowan; Pedro J del Nido; Sidney Levitsky; James D McCully
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-21       Impact factor: 4.733

Review 6.  Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.

Authors:  H H Szeto; A V Birk
Journal:  Clin Pharmacol Ther       Date:  2014-09-04       Impact factor: 6.875

7.  Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function.

Authors:  Andrea M Cordero-Reyes; Anisha A Gupte; Keith A Youker; Matthias Loebe; Willa A Hsueh; Guillermo Torre-Amione; Heinrich Taegtmeyer; Dale J Hamilton
Journal:  J Mol Cell Cardiol       Date:  2014-01-09       Impact factor: 5.000

8.  RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1α-mediated mitochondrial oxidative phosphorylation and glycolysis.

Authors:  W Chen; Q Wang; L Bai; W Chen; X Wang; C S Tellez; S Leng; M T Padilla; T Nyunoya; S A Belinsky; Y Lin
Journal:  Cell Death Differ       Date:  2014-02-28       Impact factor: 15.828

Review 9.  Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure.

Authors:  An M Van Berendoncks; Anne Garnier; Renée Ventura-Clapier; Viviane M Conraads
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 10.  Mitochondria as a therapeutic target in heart failure.

Authors:  Marina Bayeva; Mihai Gheorghiade; Hossein Ardehali
Journal:  J Am Coll Cardiol       Date:  2012-12-05       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.